Surrozen Inc (SRZN)

Surrozen, Inc.'s stock has increased significantly over the last six months and year. Major shareholders have made open-market purchases, indicating positive insider sentiment. Boehringer Ingelheim achieved a research milestone for SZN-413, triggering a $5 million payment to Surrozen. The company reported its fourth-quarter and full-year 2025 financial results, highlighting a net loss but an increase in cash and cash equivalents. The plan to submit an IND application for SZN-8141 is a key upcoming catalyst.

Surrozen, Inc.'s products and services do not exhibit typical demand seasonality. The demand for its pipeline products is driven by clinical trials, regulatory approvals, and market adoption, rather than seasonal consumer patterns. The company's revenue stems more from strategic collaborations and grants than from product sales.

Surrozen, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines by modulating the Wnt pathway. They utilize proprietary platforms to create tissue-specific antibodies for stimulating regeneration in damaged tissues. Their key pipeline programs include SZN-8141, a bifunctional antibody for diabetic macular edema and wet AMD, with an IND application expected in the second half of 2026; SZN-8143, a trifunctional antibody targeting DME, wet AMD, and uveitic macular edema; SZN-413, a bi-specific antibody for retinal vascular diseases in collaboration with Boehringer Ingelheim; and SZN-113, an antibody showing preclinical efficacy in models of Fuchs' endothelial corneal dystrophy and photoreceptor degeneration. The company previously discontinued development of SZN-043 and SZN-1326 to prioritize its ophthalmology pipeline.

Surrozen, Inc. is headquartered in South San Francisco, California, with research and development operations in the San Francisco Bay Area. They have a collaboration with Boehringer Ingelheim International GmbH, a German company, but no direct global operational or market presence.

Surrozen has maintained a generally positive brand reputation within the investment community. MarketBeat's analysis indicates that Surrozen scores higher than 77% of companies evaluated and ranks 352nd out of 858 stocks in the medical sector. Analysts have given Surrozen a "Moderate Buy" consensus rating. The resignation of Dr. Shao-Lee Lin from the Board of Directors did not negatively impact the company's reputation, and the progress of its ophthalmology pipeline and achievement of research milestones contribute positively.

Surrozen, Inc. has significant institutional and insider ownership. As of April 9, 2026, 65 institutional owners held 7,141,706 shares. Major institutional shareholders include Millennium Management Llc, VR Adviser, LLC, StemPoint Capital LP, Braidwell Lp, Spruce Street Capital LP, Boxer Capital Management, LLC, 5AM Venture Management, LLC, Kalehua Capital Management LLC, Vanguard Group Inc, and Vivo Capital, LLC. Insiders hold 45.18% of the stock, with major individual and insider owners including Life Sciences Consonance, Benny Soffer, and Kevin Harold Livingston.